Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma-Reference-Cited by-同舟云学术

Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma

Published:2020-03 Issue:3 Volume:10 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer J.

Author:

Gavriatopoulou Maria,Terpos Evangelos^ORCID,Ntanasis-Stathopoulos Ioannis^ORCID,Malandrakis Panagiotis,Eleutherakis-Papaiakovou Evangelos,Papatheodorou Athanasios,Kanellias Nikolaos,Migkou Magdalini,Fotiou Despina,Dialoupi Ioanna,Roussou Maria,Kokkali Nikoletta-Aikaterini,Kastritis Efstathios^ORCID,Dimopoulos Meletios A.

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

http://www.nature.com/articles/s41408-020-0297-2.pdf

Reference17 articles.

1. Ntanasis-Stathopoulos, I., Gavriatopoulou, M., Kastritis, E., Terpos, E. & Dimopoulos, M. A. Multiple myeloma: role of autologous transplantation. Cancer Treat Rev. 82, 101929 (2019).

2. Lehners, N. et al. Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation: impact of clinical risk factors and sustained response. Cancer Med. 7, 307–316 (2018).

3. Munshi, N. C. et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 3, 28–35 (2017).

4. Terpos, E., Ntanasis-Stathopoulos, I. & Dimopoulos, M. A. Myeloma bone disease: from biology findings to treatment approaches. Blood 133, 1534–1539 (2019).

5. Landgren, O. et al. Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma. Leukemia 33, 2127–2143 (2019).

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The effect of immunomodulatory drugs on bone metabolism of patients with multiple myeloma;Expert Review of Hematology;2024-02-12

2. Novel Developments in the Treatment of Multiple Myeloma-Associated Bone Disease;Cancers;2023-11-25

3. Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy;Frontiers in Oncology;2022-08-16

4. Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study “REBUILD”;Cancers;2022-06-02

5. Recent therapeutic approaches in myeloma;Bone Cancer;2022